Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionComerica Bank
Latest Disclosed Ownership4,040 shares
Latest Disclosed Value $ 1,606,661
Comerica Bank reports 65.73% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On January 29, 2026 - Comerica Bank filed a 13F-HR form disclosing ownership of 4,040 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $1,365,116 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 11,790 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -65.73% during the quarter. The current value of the position is $1,017,272 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,040 -7,750 -65.73 1,607 -70.13 0.0064
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,790 -6,827 -36.67 5,376 -11.43 0.0202
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,617 1,364 7.91 6,071 30.31 0.0236
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,253 3,262 23.31 4,659 41.49 0.0196
2025-02-14 2024-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 13,991 12,079 631.75 3,292 527.05 0.0133
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,991 12,079 3,292 0.0110
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,912 -10,676 -84.81 526 -82.83 0.0021
2024-08-15 2024-06-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 12,588 -415 -3.19 3,059 57.39 0.0127
2024-05-16 2024-03-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 13,003 -360 -2.69 1,943 -24.01 0.0084
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 13,363 -63 -0.47 2,558 7.57 0.0118
2023-11-21 2023-09-30 13F ALNYLAM PHARMACEUTICALS COMMON 02043Q107 13,426 13,426 2,377 0.0124
2023-08-22 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -11,761 -100.00 0 -100.00
2023-01-26 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,761 34 0.29 3 -99.91 0.0214
2022-10-28 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,727 61 0.52 2,297 35.12 0.0194
2022-08-02 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,666 0 0.00 1,700 -13.22 0.0140
2022-04-27 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,666 -9 -0.08 1,959 28.12 0.0142
2022-02-18 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,675 -2 -0.02 1,529 -34.07 0.0113
2021-11-22 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,677 -3,304 -22.05 2,319 -21.42 0.0140
2021-08-26 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,981 -196 -1.29 2,951 42.22 0.0176
2021-04-28 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,177 -409 -2.62 2,075 -22.75 0.0124
2021-01-28 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,586 -345 -2.17 2,686 27.90 0.0170
2020-10-30 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,931 -110 -0.69 2,100 -17.13 0.0152
2020-07-31 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,041 -4,746 -22.83 2,534 -16.29 0.0195
2020-05-01 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,787 -3,733 -15.22 3,027 6.92 0.0278
2020-02-07 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,520 -1,296 -5.02 2,831 23.36 0.0214
2019-10-31 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,816 -5,643 -17.94 2,295 0.39 0.0181
2019-08-02 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,459 4,156 15.22 2,286 -7.90 0.0183
2019-05-02 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,303 1,636 6.37 2,482 22.21 0.0201
2019-02-06 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,667 3,579 16.20 2,031 20.04 0.0173
2018-11-01 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,088 5,956 36.92 1,692 2.61 0.0136
2018-08-01 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,132 22 0.14 1,649 6.46 0.0115
2018-05-01 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,110 -47 -0.29 1,549 -28.42 0.0111
2018-02-02 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,157 272 1.71 2,164 10.80 0.0144
2017-11-06 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,885 198 1.26 1,953 49.08 0.0141
2017-08-03 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,687 -54 -0.34 1,310 57.64 0.0098
2017-05-03 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,741 -528 -3.25 831 22.75 0.0063
2017-02-08 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,269 2,712 20.00 677 37.88 0.0054
2016-11-10 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,557 -157 -1.14 491 -53.15 0.0290
2016-08-11 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,714 31 0.23 1,048 11.37 0.0091
2016-05-11 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,683 89 0.65 941 -18.25 0.0084
2016-02-05 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,594 -233 -1.69 1,151 3.60 0.0113
2015-11-12 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,827 -13,697 -49.76 1,111 -66.31 0.0105
2015-08-13 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,524 13,814 100.76 3,298 130.47 0.0142
2015-05-15 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,710 -13,656 -49.90 1,431 -46.08 0.0121
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,366 13,683 100.00 2,654 148.50 0.0115
2014-10-21 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,683 -37 -0.27 1,068 23.18 0.0094
2014-08-12 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,720 -4,540 -24.86 867 -29.28 0.0074
2014-05-15 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,260 13 0.07 1,226 4.43 0.0094
2014-02-11 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,247 -1,544 -7.80 1,174 -7.34 0.0091
2013-11-12 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,791 -86 -0.43 1,267 105.68 0.0088
2013-08-13 2013-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 19,877 19,877 616 0.0050
2013-08-08 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 52,508 1,628
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.